Clinical Trial

A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B

Study acronym: HBV
Completed Phase 1
View on ClinicalTrials.gov →
Summary
Phase 1 Study of BW-20507 in Healthy Subjects and Patients With Chronic Hepatitis B. Ia involved a single ascending dose study where healthy participants were administered one dose of BW-20507 or placebo subcutaneously. Ib involved a multiple ascending dose study where participants with chronic hepatitis B virus infection were administered with multiple doses of BW-20507 SC
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-12.
Trial Details
NCT Number NCT07595159
Lead Sponsor Shanghai Argo Biopharmaceutical Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 32 participants
Start Date 2024-06-24
Primary Completion 2025-11-18 (estimated)
Study Completion 2025-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-31